The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Herbert Aaron Eradat
Research Funding - Gilead Sciences
Tadeusz Robak
Research Funding - Gilead Sciences
Julio Delgado
Research Funding - Gilead Sciences
Anna Schuh
Research Funding - Gilead Sciences
Alexander S. Pristupa
Research Funding - Gilead Sciences
Joanna Omyla-Staszewska
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Research Funding - Gilead Sciences
Charles Michael Farber
Research Funding - Gilead Sciences
Donald MacDonald
Research Funding - Gilead Sciences
Abraham Jacob
Research Funding - Gilead Sciences
Jeff Porter Sharman
Research Funding - Gilead Sciences
Javier Loscertales
Research Funding - Gilead Sciences
Jennifer R. Brown
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Shelley Evans
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences